DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: Eli Lilly Nederland B.V.
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Portrazza, with its generic name Necitumumab, is a monoclonal antibody developed by Eli Lilly and Company. It received approval from the United States Food and Drug Administration (FDA) in late 2015, marking a significant advancement in the treatment of advanced squamous NSCLC.
